Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duglow (dapagliflozin + pioglitazone) add-on to metformin in Korean patients with type 2 diabetes mellitus
KCT0009940Phase 4Recruiting
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by Jeil Pharmaceutical Co., Ltd.. Started Oct 2024; status: recruiting.
02
Drugs
dapagliflozinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0009940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009940.